Mangalam Drugs and Organics Limited is an India-based company, which is engaged in the manufacture of drugs, medicines and allied products. The Company's geographical segments include Domestic and Export. It also manufactures active pharmaceutical ingredients (APIs), intermediates and specialty chemicals. Its API products include Allopurinol, Amodiaquine HCl, Artemether, Atazanavir Sulfate, Bisoprolol Fumarate, Lumefantrine, Primaquine Phosphate and Pyronaridine Tetraphosphate. Its intermediates include 4-Bromo-1-phthalimidopentane, 2-Aminodiphenyl Ether/2-Phenoxyaniline, 6-chloro-5-fluoro-1H-indole, 6-chloro-5-fluoro-1H-indole-3-carbaldehyde and 7, 10-dichloro-2-methoxybenzo(b)-1,5-naphthyridine. Its specialty chemicals include L (+)-Menthol, 2, 3-Dihydrophthalazine-1, 4-dione OR Phthalazine-1, 4-dione and 4-Cynoethyl-2-methyl Phenol. It has a range of products that involves various chemistries, including Acylations, Polymoph Transformations, Chlorination and Hydride Reductions.
Ford US Equity Research covers more than 4,000 stocks using a proprietary quantitative model that evaluates a company’s earnings strength, its relative valuation and recent price movement. Ford’s five recommendation ratings include strong buy, buy, hold, sell, strong sell. For all stocks in our coverage universe, ratings are generated each week and reflect the fundamental and price data as of the last trading day of the week.
Ford Equity International Research Reports cover 60 countries with over 30,000 stocks traded on international exchanges. A proprietary quantitative system compares each company to its peers on proven measures of business value, growth characteristics, and investor behavior. Ford's three recommendation ratings buy, hold and sell, represent each stock’s return potential relative to its own country market.. The rating reports which are generated each week, include the fundamental details behind each recommendation and reflect the fundamental and price data as of the last trading day of the week.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.